BioMAdvanced Diagnostics develops biomarker tests for kidney and lung transplant patients, utilizing 20 years of translational research to identify and predict transplant rejection risks. Their minimally invasive solutions aim to enhance patient outcomes while significantly reducing healthcare costs through improved treatment personalization.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney and lung transplant recipients face the risk of transplant rejection, which can lead to graft failure and increased morbidity. Current methods for monitoring transplant health are often invasive or lack the sensitivity to detect early signs of rejection. This can result in delayed treatment and poorer patient outcomes.
Solution
BioMAdvanced Diagnostics develops minimally invasive biomarker tests to assess and predict transplant rejection risk in kidney and lung transplant patients. By leveraging translational research in immune system biomarkers, their diagnostic solutions aim to provide clinicians with tools to personalize treatment strategies. These tests offer predictive scores that can be easily integrated into existing diagnostic and treatment protocols, enabling earlier intervention and improved patient management.
Target Audience
The primary target audience includes clinicians and medical practitioners involved in the care of kidney and lung transplant patients, as well as hospitals and transplant centers.
Features
- Focus on kidney and lung transplant monitoring
- Tests based on biomarkers related to the immune system
- Minimally invasive approach to reduce patient risk
- Predictive scores for assessing transplant rejection risk
- Designed for easy integration into standard treatment protocols
- Aims to improve patient outcomes through personalized medicine